Hiroshima University
Background: The current standard treatment for chronic hepatitis C is pegylated-interferon and ribavirin combined therapy. However, to a minority of patients, interferon monotherapy is still applied to prevent severe side effects. We investigated host genetic factors affecting treatment efficacy of interferon in patients with CHC. Methods: Using a two-step design, a large scale association screening including 1088 Japanese CHC patients (HCV 1 and 2) treated with interferon was performed employing approximately 70,000 SNPs. Replication was tested in an independent Japanese cohort of 328 CHC patients. Fine mapping around association signals and functional analyses were performed to identify causal variant. Results: Through the screening stage, we found rs12286580 in intron6 of polypeptide N-acetylgalactosaminyltransferase 8 (GAL-NT8) on chromosome 12 was significantly associated with sustained viral response (combined-p = 4.1 9 10-7, OR 1.49, 95%CI 1.26-1.76). The association was replicated in an additional Japanese cohort (overall-p = 7.6 9 10-8, OR 1.58, 95% CI 1.29-1.72). Through resequencing and fine mapping, rs10849138 in intron6 showed the most significance (p = 1.8 9 10-8). Subgroup analysis stratified by HCV genotype revealed that there was no heterogeneity between HCV genotypes in the association with treatment outcome. By contrast, the outcome of pegylated-interferon and ribavirin combined therapy was not affected by the SNP. Luciferase reporter assay demonstrated that overexpression of GALNT8 attenuated IFN-alfainduced gene transcription via ISRE elements. Conclusions: We identified a novel genetic variant in GALNT8 affecting IFN treatment outcome against CHC in Japanese population. Our functional analysis suggested that GANLT8 inhibits interferonalfa induced antiviral activity.
National Taiwan University College of Medicine, 10 National Taiwan University College of Medicine Background: Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a significantly higher risk of developing advanced liver disease or hepatocellular carcinoma than monoinfected patients. Our previous study showed a similar rate of HCV clearance at 6 months after the end of peginterferon alfa-2a and ribavirin combination therapy in these patients, compared to HCV monoinfected patients. We followed the rate of sustained HCV clearance for up to 5 years after the end of treatment. Methods: Patients with active HCV genotype 1, both HBV coinfected (n = 97) and monoinfected patients (n = 110), received a 48-week combination therapy with peginterferon alfa-2a 180 mcg weekly plus daily ribavirin 1000-1200 mg (body weight \75 kg, 1000 mg; C75 kg, 1200 mg). Patients with active HCV genotype 2/3, both HBV coinfected (n = 64) and monoinfected (n = 50) patients received a 24-week combination therapy with peginterferon alfa-2a 180 mcg weekly plus daily ribavirin 800 mg. A total of 26 (8.1%) patients were withdrawn prematurely from the study; 253 (78.8%) patients of the original cohort agreed to receive post-treatment followup for up to 5 years. Results: After a median follow-up of 3.5 years (range: 1-5 years) after the end of treatment, 8 (3.3%) of the 242 patients who had undetectable serum HCV RNA at 24 weeks post-treatment developed HCV RNA reappearance, including 5 HCV genotype 1/HBV coinfected patients, 1 HCV genotype 1 monoinfected patient and 2 HCV genotype 2/3 monoinfected patients. The time of relapse was 1 year in 3, 2 years in 3, 3 years in 1 and 4 years in 1 patient, respectively, after the end of treatment. Conclusions: Peginterferon alfa-2a and ribavirin combination therapy provides a good rate of HCV clearance in patients dually infected with HCV and HBV. HCV clearance was sustained in the majority of patients who obtained HCV clearance 24 weeks posttreatment.
PS06-04
Telbivudine (LDT) Treatment Associated with Improvement of Glomerular Filtration Rate (GFR) Pitie Salpetriere Hospital, 6 Klinikum der Johann Wolfgang Goethe-Universitaet, 7 Beijing Friendship Hospital, Capital Medical University, 8 The Second Affiliated Hospital, Chongqing Medical University, 9 Novartis Pharma AG, 10 Novartis Pharma AG Background: Data from *2500 telbivudine treated patients for up to 6-years shows consistent GFR improvement across 7 different studies including compensated or decompensated CHB patients. Methods: In GLOBE study, GFR improvement was assessed in patients with baseline age [ 50 yrs; or with baseline GFR 60-80 ml/ min/1.73m2. The association between GFR improvements (change [0 or shift to a higher category) vs. undetectable HBV DNA was explored. In A2301 study in decompensated CHB patients, the association between GFR improvements vs. ascites or diuretics or MELD score was explored. Results: In GLOBE study patients with baseline age[50 yrs, GFR (LSmeans±SE) changed by +8.4±1.8 (LDT) vs. -3.4±1.7 (LAM) at 2yrs (p\0.0001). 67.2% (82/122) of LDT-treated patients with baseline GFR 60-80 shifted to [90ml/min/1.73m 2 at 2yrs vs. 46.9% (45/96) in LAM. Chi-Square test showed the percentage of LDTtreated patients with GFR improvement was not different (p[0.05) in patients with or without undetectable HBV DNA at Week104. In A2301 study, percentage of patients with GFR improvement was not different (p[0.05) in LDT treated patients with or without ascites during 2yrs study period. No association with CTP score or the use of diuretics was observed. A difference (p=0.03) was observed in LAM treated patients: 2.4% patients with ascites had GFR improvement vs. 16.2% without ascites had GFR improvement. Patients with improved MELD score had a higher rate of GFR improvement. Conclusions: LDT treatment improved GFR in patients with older age or abnormal GFR. It's not associated with undetectable HBV DNA, ascites or use of diuretics.
PS06-05
Five years of treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis Edward Gane University of Hawaii at Manoa, Honolulu, HI, biopsies were performed at year 5 and reviewed by an independent pathologist. Results: Of 641 patients randomized and treated, 585 (91%) entered the TDF extension phase; 489 (76%) remain on study at year 5. Paired histologic liver assessments at baseline (BL) and year 5 were available for 348 (54%) patients. 87% showed histologic improvement (M=E); 96% of patients improved or showed no worsening of fibrosis by Ishak scoring, and 74% of cirrhotic patients at baseline had regression of histologic cirrhosis. At 5 years, 98% of patients on therapy had HBV DNA\400 copies/mL, and ALT normalization was achieved by 85%, and 73% of HBeAg-and HBeAg+ patients. HBsAg loss (KM%) was observed in 10% of HBeAg+ patients; 1 HBeAgpatient also had HBsAg loss at Week 240. TDF was safe and well tolerated; resistance has not been detected to TDF through year 5. Conclusions: TDF remains safe and effective over a 5 year period. These data establish the link between long-term HBV suppression with TDF and regression of advanced fibrosis in the majority of treated patients.
PS06-06
S-Collate cohort study: on-treatment HBsAg level analysis in real-life confirms prediction of response observed in NEPTUNE and phase III studies of peginterferon alfa-2a in HBeAg-positive patients XinYeu Chen Background: S-Collate is a multinational, observational cohort study investigating on-treatment predictors of hepatitis B surface antigen (HBsAg) clearance in peginterferon alfa-2a (Peg-IFNa-2a) (40KD)-treated chronic hepatitis B (CHB) adults. This interim assessment investigates association between on-treatment HBsAg cut-offs identified in previous studies and week 48 response rates in hepatitis B e-antigen (HBeAg)-positive patients. Methods: HBeAg-positive patients treated with Peg-IFNa-2a, HBsAg-positive at baseline, with treatment starting Results: Of the 526 patients included, 71.1% were male, median age 29 years and 80.3% Asian/Oriental. Of 163 patients with genotype data, 40.5% were genotype C. At week 48, 24.0% of patients achieved HBV DNA \2000 IU/mL. By week 48, 19.8% and 2.3% of patients achieved HBeAg seroconversion and HBsAg clearance, respectively, HBsAg Conclusions: On-treatment measurements of HBsAg in a real-life cohort were associated with week 48 HBeAg seroconversion and HBsAg clearance rates in HBeAg-positive patients, with highest endof-treatment response rates in patients with HBsAg levels \1500 IU/ mL at weeks 12 and 24. These data support findings from phase III and NEPTUNE studies.
PS07-01
Epigenetic regulation of microRNA expression in alcoholic liver injury Fanyin Meng, Shannon Glaser, Heather Francis, Fuquan Yang, Dustin Staloch, Yuyan Han, Allison Stokes, Chang-Gong Liu, Hidekazu Tsukamoto, Gianfranco Alpini Scott & White Hospital, Texas A&M HSC College of Medicine Background: Epigenetic changes are associated with the regulation of transcription of key cell regulatory genes (miRNAs) during different types of liver injury. The objective of this study was to evaluate the role of methylation associated miRNA, miR-34a in alcoholic liver disease. Methods: miRNA expression in alcoholic liver tissues and cells was assessed using a hybridization based microarray and expression of selected miRNA was verified by Taqman real-time PCR analysis. Results: Four weeks of ethanol feeding significantly up-regulated 0.8% of known miRNAs, including miR-34a. In ALD mice liver, ethanol treatment also significantly decreased expression of the DNA methyltransferase enzyme DNMT-3B and DNMT1. Treatment of normal human hepatocytes (N-Hep) and cholangiocytes (HiBEC) with ethanol induced a significant increase of miR-34a expression. Over-expression of miR-34a or silencing DNMT-3B significantly decreased ethanol-induced apoptosis in both N-Hep and HiBEC cells. As the 5-promoter region of miR-34a was noted to be embedded within a CpG island, the expression level of miR-34a was significantly increased after de-methylation treatment in N-Hep and HiBEC cells. A combination of bioinformatics, dual-luciferase reporter assay, mass spectrometry and western blot revealed that Caspase-2 and Sirtuin 1 are the direct targets of miR-34a. Furthermore, modulation of miR-34a also altered expression of matrix metalloproteases 2 and 9, the mediators involved in hepatic remodeling during alcoholic liver fibrosis.
Conclusions:
The discovery provides the basis for an exciting field in which the epigenomic microRNAs of hepatic cells may be manipulated with potential therapeutic benefits in human alcoholic liver diseases. 
PS07-02

PS07-03
The effect of single gene polymorphisms (SNPs) at different loci in PPAR-c gene on the natural course of non-alcoholic fatty liver disease (NAFLD) Yongjian Zhou
Guangzhou First Municipal Peoples Hospital, Guangzhou Medical College
Background: We have showed that the SNPs at C161T and C681G in PPAR-cgene, but not at C-689T and Pro12AlaAwere associated with susceptibility to NAFLD (another abstract). In this prospective cohort study, we investigate the effect of the four SNPs on the natural course of NAFLD. Methods: 696 subjects(median age 50)were followed-up for a median of 4 years (range: 3.6-4.8). Interviews, physical examinations, biochemical tests, and abdominal ultrasonography were repeated for each subject. PCR-RFLP was applied to determine SNPs in the four loci of PPAR-c gene. The present and severity of NAFLD was determined mainly by ultrasonography. Multivariate regression logistic analysis was performed to evaluate the risk factors. Results: In a total of 696 subjects, 350 remained normal both at baseline and endpoint, 202 normal subjects at baseline developed NAFLD at endpoint. Among 144 NAFLD patients at baseline 64 (44.5%) remained unchanged, 31 (21.5%) became worse and 49 (34.0%) improved at endpoint. After adjusting for age and gender, The subjects, who hold variant of C to G substitution at C-681G had higher possibility (148% increase) of getting worse than wild genotype.(P=0.002,OR=1.48). C-689T, Pro12Ala and C161T did not affect the natural course of NAFLD (P[0.05).
Conclusions:
The SNPs of C-681G, but not C-689T, Pro12Ala and C161T conferred the risk for NAFLD progression. Background: In animal model of nonalcoholic fatty liver (NAFL), the function of autophagy is impaired and hepatocytes always suffer apoptosis. Considering autophagy is an alternative pathway for regulating lipid stores in hepatocyte, we suggest that autophagy could also play a protective role in NAFL. Methods: HepG2 cells were cultured in DMEM contained oleate with or without LY294002. Autophagy and apoptosis were assessed by detecting GFP-LC3 puncta and M30 immunoreactivity, respectively. Results: We found that HepG2 cells cultured with oleate could finally be induced to experience apoptosis (24 hours), with high level of autophagy development and high levels of mRNA of p53 target genes (PUMA and p21). Our results were in accordance with the results of animal model and suggested p53 could involve in apoptosis development. However, we also found autophagy could also be induced at 8 hours when apoptosis was failed to be observed, with low expression of p53 target genes, suggesting a protective role of autophagy in preventing apoptosis. Through blocking autophagy by LY294002, we found that, at 8 hours (but not 24 hours), apoptosis could be induced and the expression of p53 target genes was increased. Furthermore, we found oleate could increase ATP production at 8 hours and LY294002 treatment could not prevent ATP production increasing, confirming that autophagy plays a protective role in preventing hepatocytes from apoptosis. Conclusions: Our results suggested that promoting early and inhibiting late autophagy development in NAFL might be beneficial for improving curative effect of NAFL.(This work was supported by grants from NSCF30870853, 7092045 and 7101005.)
PS07-04
PS07-05
The effectiveness of glucagon like peptide 1 analogue in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus compared to dipeptidyl peptidase-4 inhibitor Takamasa Ohki, Akihiro Isogawa, Tomoko Takeda, Takafumi Ooga, Koki Sato, Hitoaki Fujiwara, Kei Saito, Michiharu Seki, Nobuo Toda, Kazumi Tagawa
Mitsui Memorial Hospital
Background: The aim of this study is to elucidate the effectiveness of glucagon like peptide 1 analogue (GLP-1) in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (DM) compared to dipeptidyl peptidase-4 inhibitor (DPP-4I). Methods: We enrolled 126 Japanese NAFLD patients with type 2 DM between 2003 April 1st and 2011 March 31st. We finally divided these patients into GLP-1 treated group and DPP-4I treated group. We compared the base line characteristics and also compared the changes of ALT level, AST to platelet counts ratio index (APRI), blood glucose (BS) level, hemoglobin A1c (HbA1c) level and body weight between the two groups at the end of follow-up. The significant factors which affected on body weight reduction for more than 5% after the treatment was assessed by multivariate regression analysis. Results: There were 26 patients treated with GLP-1 and 36 patients treated with DPP-4I. At the end of follow-up, ALT level (GLP-1 -26.2%, DPP-4I -18.7%), BS level (GLP-1 -23.2%, DPP-4I -15.1%), and HbA1c level (GLP-1 -10.5%, DPP-4I -15.1%) markedly improved in both groups. The body weight and APRI significantly decreased in GLP-1 group (-4.4% and -32.9%, respectively P \ 0.05). However, those two factors did not change in DPP-4I group. Multivariate analysis indicated that administration of GLP-1 as an independent factor of body weight reduction for more than 5% (OR 22.0; 95%CI 1.68-289, P = 0.02).
Conclusions:
The administration of GLP-1 significantly improved not only ALT level and APRI but also body weight in NAFLD patients with type 2 DM. 
PS07-06
PS08-06
Radiologic response to transcatheter hepatic arterial chemoembolization in hepatocellular carcinoma predicts patient survival times Hong Joo Kim, Chang Seck Song, Yong Kyun Cho, Byung Ik Kim
Sungkyunkwan University Kangbuk Samsung Hospital
Background: The aim of the current study is to analyze the association between radiologic tumor response and survival times of patients with hepatocellular carcinoma (HCC) who were treated with transcatheter hepatic arterial chemoembolization (TACE). Methods: Among 374 consecutive patients presenting to our institution between October 2000 and October 2007 with radiologically (n = 132) or histologically (n = 18) confirmed HCC, 150 patients who exclusively underwent TACE and had confirmed survival data were retrospectively reviewed. The radiologic response was assessed using WHO and EASL necrosis criteria at 1 month after the initial TACE. Results: Median survival was 37 and 9 months for responders and nonresponders, respectively by WHO criteria (p \ 0.01); Median survival was 28 and 4 months for responders and nonresponders, respectively by EASL criteria (p \ 0.01). By univariate analysis, higher Child-Turcotte-Pugh (CTP) score, bilobar and multifocal distribution of tumors, larger tumor size ([5 cm), higher serum alfafetoprotein (AFP) level ([200 ng/ml), advanced ECOG, UNOS and BCLC staging, and nonresponder (SD or PD) in WHO and EASL response assessment were significantly associated with shorter overall survival times. By cox proportional hazard model adjusting for age and sex of enrolled patients, only EASL response criteria was independent and significant prognosticator for overall survival times in patients with HCC who exclusively underwent TACE. Conclusions: Radiographic response assessed at 1 month after initial TACE predicts overall survival times. EASL criteria for response more consistently predicted overall survival times than WHO criteria. The goal of TACE should be to achieve a radiologic response, rather than to stabilize disease.
PS09-01
Preoperative We analyzed 160 patients after excluding 3 cases of early mortality and 6 cases of macrovascular invasion which was found during the preoperative evaluation and 9 cases of incidental diagnosis of HCC after LDLT. We investigated disease free survival rate (DFS), overall survival rates and effectiveness of biological markers including AFP and PET positivity. Results: Among 160 patients, 5 year DFS and 5 year survival rate (YSR) were 78.7% and 78.8% respectively. Five year DFS were 83.6% (n = 126) in group within Milan criteria and 60.9% (n = 34) in group beyond Milan criteria) (p \ 0.001). Overall 5 YSR were 83.5% (n = 126) in former group and 61.4% (n = 34) in latter group (p = 0.011). Among the 15 patients with HCC beyond Milan criteria and typical biological factors (AFP\200, PET negativity), only 2 cases were recurred. Conclusions: Milan criteria is too restrictive to give enough information of the prognosis for the patients with HCC. Tumor biological markers have the possibility to overcome the limitation of the Milan criteria. Preoperative serum AFP level and 18F-FDG PET positivity of HCC predict the tumor recurrence better than Milan criteria in LDLT.
PS09-02
RNA Interference Targeting RelB Attenuates Liver Ischemia-Reperfusion Injury in Mice Li Feng, Lei Luo, Juan Shan, Yingjia Guo, Shengfu Li, Youping Li
West China Hospital, Sichuan University
Background: RNA interference targeting RelB can significantly attenuate ischemia-reperfusion (I/R)-induced renal dysfunction, but its roles in I/R injury of liver transplantation remain to be defined. We have investigated whether siRNA targeting of RelB in liver could also elicit protection against I/R injury.
Hepatol Int (2012) 6:44-66 49
Methods: A RelB miRNA RNAi expression plasmid, a scrambled plasmid or PBS (50 gg of the plasmid diluted in PBS, 8% w/v) were rapidly injected, within 6V8 seconds, into mouse tail veins 24 hours before liver I/R. Mice were subjected to 30 minutes of 70% hepatic ischemia or to a sham operation. Six hours after reperfusion, blood and liver tissue samples were collected for subsequent assays.
Results: The expression level of RelB was reduced in the RelB RNAi group compared with the control group, while it was increased in the I/R group. In the sham group, malondialdehyde (MDA), myeloperoxidase (MPO) and superoxide dismutase (SOD) serum levels were almost the same, but the serum alanine aminotransferase (ALT) level in the untreated group was 20V25-fold lower than in the other groups. In I/R treated mice, although ALT, MDA and MPO serum levels in the RelB RNAi group were lower than in other groups, all were higher than in the sham group. Silencing RelB could inhibit the decrease of SOD activity and the up regulation of MPO and TNF-alpha induced by I/R injury. Conclusions: In conclusion, silencing RelB can protect the liver against I/R induced damage. Therefore, it is a promising therapeutic target for protection against I/R injury in the liver.
PS09-03
Successful continuous unlimited monthly HB vaccination in liver transplant recipients for Hepatitis B virus-related end stage liver disease Shoichi Takahashi, Tomokazu Kawaoka, Shintaro Takaki, Takashi Onoe, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama
Hiroshima University
Background: The aim of this study is to evaluate the efficacy of HB vaccination in liver transplant recipients in our institute. Methods: Twenty-five patients were vaccinated with conventional recombinant vaccine containing 10 or 20 gg HBsAg every month. All patients received 1,000 or 2,000 IU HBIG every month. HB vaccination and HBIG administration were continued until anti-HBs levels reached [300 IU/L and then both HBIG and HB vaccination were withdrawn subsequently. Results: Fourteen of 25 patients successfully achieved a good response with [200 IU/L of anti-HBs titer after HBIG and HB vaccine withdrawal. Twelve were liver cirrhosis cases and 2 were fulminant hepatic failure cases. In 11 of 14 successful cases, nucleotide reverse transcriptase inhibitor could be withdrawn after HBIG and HB vaccine withdrawal. Median duration of HB vaccination was 16 months, and the dose of HB vaccine was 10 gg in 6 cases and was raised to 20 gg in 8 cases. The dose of HBIG was 1,000 IU/L/month in all successful cases, especially in 4 cases, anti-HBs titer reached [300 IU/L after HBIG dose reduction from 2,000 IU/L to 1,000 IU/ L. The falling of anti-HBs titer \200 IU/L was experienced after HBIG and HB vaccine withdrawal in 8 of 14 successful cases, however, a few times of HB vaccine re-administration restored antiHBs titer up to [300 IU/L in all cases. Conclusions: 1) Continuous unlimited monthly HB vaccination, 2) less and sufficient dose of HBIG and immunosuppressant administration, were important for good response with HB vaccination for the liver transplant recipients for HBV-related liver disease,
PS09-04
Functional role of the miR-17-92 cluster in human gall bladder cancer stem cells Fanyin Meng, Heather Francis, Shannon Glaser, Yuyan Han, Jay Sharma, Chang-Gong Liu, Gianfranco Alpini
Scott & White Hospital, Texas A&M HSC College of Medicine
Background: MicroRNAs (miRNAs) are endogenous molecules which negatively regulate the expression of a variety of genes. Our aims were to characterize the functional roles of the microRNAs in human gall bladder cancer stem cells.
Methods: Human gall bladder cancer stem cells (GB-CSCs) were isolated from human gall bladder cancer tissues using Oct-4 and CD133 as the specific markers. miRNA expression in human gall bladder cancer tissues as well as GB-CSCs and Mz-ChA-1 cells was assessed using a hybridization based microarray and expression of selected miRNA was evaluated by Taqman real-time PCR analysis. Results: Five among six members of the miR-17-92 cluster showed significant increased expression in human gall bladder cancer tissues, and GB-CSCs relative to Mz-ChA-1 cells. Significant correlation between the expression of c-myc and the six miRNAs was discovered.
Introduction of c-myc siRNA to GB-CSCs significantly reduced miR-17, miR-19a, miR-19b, miR-20a and miR-92a expression, and subsequently reduced the chemosensitivity to gemcitabine and sorafenib. The tumor suppressor genes PTEN and p21(CDKN1A) were shown to be the direct targets of miR-17-92, and c-myc transfection reduced the expression of PTEN and p21 in Mz-ChA-1 malignant cholangiocytes. Modulation of miR-17-92 cluster altered expression of PTEN and p21 in both GB-CSCs and Mz-ChA-1 cells, and subsequently affected chemosensitivity to gemcitabine and sorafenib, as well as the transformed cell growth in soft agar. Conclusions: Our results define a novel regulatory mechanism of specific microRNA group and suggesting that miR-17-92 cluster may be the molecular targets for eradication of gall bladder cancer.
PS09-05
Applying the 6-months rule in living donor liver transplantation candidates with alcoholic liver disease: University of Tokyo experience Kayo Nojiri, Noriyo Yamashiki, Yoshikuni Kawaguchi, Sumihito Tamura, Junichi Kaneko, Taku Aoki, Kiyoshi Hasegawa, Yasuhiro Sakamoto, Yasuhiko Sugawara, Norihiro Kokudo
University of Tokyo
Background: End-stage alcoholic liver disease (ESALD) is one of the most common indications for liver transplantation, and 85% of transplant centers in the United States require at least 6 months of abstinence from alcohol use before listing for transplant. We report the outcome after the evaluation for living donor liver transplantation (LDLT) in patients with ESALD. Methods: Between 1996 and 2010, 465 LDLT were performed at University of Tokyo, and 11 (2.3%) were for ESALD. During the same period, 80 patients with ESALD were evaluated for candidacy. Six months of abstinence was required for all candidates. Results: Five of 11 recipients had comorbid hepatocellular carcinoma (HCC) and 1 had HCV infection. The median follow up period was 3.5 (0.9 V 8.7) years. One died due to recurrent HCC 357 days after LDLT. Among 10 survivors, 9 remained abstinence, and 1 relapsed but stopped drinking after counseling. Patients who did not meet 6-months rule were referred to psychiatrist for intervention; 8 patients refused abstinence from alcohol, and 14 were active drinkers. Three patients who remained on abstinence improved their liver function. Most common reasons for patient rejection in remaining candidates were comorbidity and lack of family/social support. Conclusions: Post-operative course after LDLT was excellent without returning to abusive alcohol drinking. The 6-months rule may prevent relapse drinking after LDLT.
PS09-06
Comparison 
resection (SR) or transarterial chemoembolization (TACE).
Methods: A total of 268 and 455 HCC patients beyond the Milan criteria undergoing SR and TACE, respectively, were retrospectively evaluated. After propensity score analysis to adjust for baseline differences, 146 pairs of matched patients were selected from each treatment arm. Long-term survival was compared by the KaplanMeier method. Independent prognostic predictors were determined by the Cox proportional hazards model. Results: Long-term survival was significantly better for the SR group by univariate survival analysis (p \ 0.001). In the Cox model, SR was identified as an independent predictor of better prognosis (hazard ratio = 0.3, 95% confidence interval [CI]: 0.23-0.4, p \ 0.001). Despite similar baseline characteristics in the propensity score model, patients who underwent SR had significantly better survival than patients who underwent TACE (p \ 0.001). Patients receiving TACE had 1.44-fold increased risk of long-term mortality in the propensity model (95% CI: 1.65-3.59). The SR and TACE groups had comparable 30-and 90-day post-treatment mortality. The Cox model consistently disclosed the significant superiority of SR in terms of long-term survival in the propensity score model (p \ 0.001) Conclusions: For HCC patients beyond the Milan criteria, SR is considered equally safe as TACE and provides better long-term survival. SR may be regarded as the priority treatment for these patients.
PS10-01
HBV DNA synthesis influenced by the nuclear-cytoplasmic shuttling of HBV core protein and the cellular machinery of the TAP-p15 complex Ching-Chun Yang, Er-Yi Huang, Hung-Cheng Li, Pei-Yi Su, Chiaho Shih
Academia Sinica
Background: Amplification of HBV ccc DNA can be facilitated by the nuclear-cytoplasmic shuttling of HBV RNA pregenome and DNA genome. Previously, we reported that the nuclear export of HBV core protein (HBc) is dependent on a cellular protein Tap/NXF1. Both relaxed circular (RC) form and single strand DNA (SS) were reduced by the treatment with siRNA TAP. (Li et al., PLoS Pathogens, 2010) . The Tap protein is known to be associated with another cellular factor p15/NXT1, and form a stable heterodimer Tap-p15 complex. We investigated further the mechanism of this TAP-dependent viral DNA synthesis phenomenon. Methods: Here, we first investigated the role(s) of p15 in HBc subcellular localization by confocal immunofluorescence microscopy, viral DNA synthesis by Southern blot, HBV pgRNA export by the luciferase reporter assay, and its potential physical interaction with HBc by co-immunoprecipitation. Results: Treatment of siRNA specific for Tap-p15 complex resulted in dramatic nuclear accumulation of HBc. HBc ARD can physically and specifically interact with the TAP-p15 complex. Furthermore, both HBV DNA synthesis and pgRNA export were reduced by the treatment with siRNA Tap and p15. Conclusions: The virological significance of the physical and functional association of HBc with the Tap-p15 complex will be discussed in the context of HBV DNA synthesis.
PS10-02
Higher hepatitis B surface antigen level increases risk of HBeAg-negative hepatitis in HBV carriers with low viral load Taichung Tseng, Chun-Jen Liu, Hung-Chih Yang, Tung-Hung Su, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao Buddhist Tzu Chi General Hospital Taipei Branch, New Taipei City, Taiwan
Background: HBeAg-negative hepatitis (ENH) is a leading event for cirrhosis and hepatocellular carcinoma development in patient with chronic hepatitis B virus (HBV) infection. Recent data has indicated that a lower HBsAg level is associated with a favorable outcome of HBsAg loss. However, it remains unknown whether a higher HBsAg level increases ENH risk in HBV carriers, especially in those with a low viral load. Methods: A total of 1068 Taiwanese HBsAg-positive, HBeAg-negative patients without evidence of cirrhosis at study entry were enrolled. All of them had HBV-DNA level \2000 IU/mL and did not receive any anti-viral therapy during the follow-up period. After excluding 40 patients who have already had baseline ALT level [80 IU/mL, a total of 1028 patients were included into our analysis. Results: With a mean follow-up of 13.2 years, 251 patients developed ENH with an average annual incidence rate of 1.8%. Univariate analysis showed that sex, age, ALT level and HBsAg level 1000 IU/ mL, but not HBV-DNA level, are risk factors of ENH. Compared to patients with HBsAg level \1000 IU/mL, the hazard ratio of ENH was 1.5 (95% confidence interval, 1.2-1.9) for HBsAg level 1000 IU/ mL. Multivariate analysis showed that HBsAg 1000 IU/mL is still an independent risk factor of ENH with adjusted hazard ratio of 1.6 (1.3-2.1). Conclusions: In a cohort of 1028 HBeAg-negative HBV carriers with baseline HBV-DNA level\2000 IU/mL, HBsAg level 1000 IU/mL is associated with a higher risk of HBeAg-negative hepatitis over time. 
PS10-03
Cipto Mangunkusumo Hospital
Background: Recently, quantitative HBsAg has been used as a predictor for antiviral therapy in chronic hepatitis B (CHB) patients. Its association with intrahepatic cccDNA and liver fibrosis remains controversial. This study was aimed at determining any association between serum qHBsAg, intrahepatic hepatitis B virus (HBV) cccDNA and hepatic fibrosis in CHB patients. Methods: CHB patients were recruited from September 2009 to June 2011. HBsAg quantification was performed using the Abbott HBsAg QT assay. Intrahepatic HBV cccDNA was measured from biopsy specimens using a real-time PCR assay. Biopsy specimens included at least 5 portal systems to be eligible for evaluation using the METAVIR score. Results: 104 patients were enrolled; 54 (51.9%) were male. Chang Gung Memorial Hospital Background: It is common to observe the clustering of chronic hepatitis B surface antigen carriers and hepatocellular carcinoma patients in families. Intra-familial transmission of hepatitis B virus could be the reason for the clustering of chronic hepatitis B seen in families. Additionally, genetic factors and sex hormones have been reported to be involved. Methods: A total of 304 male controls and 321 male chronic hepatitis B surface antigen carriers were included in the multi-stage genomewide association study. The whole-genome genotyping was done on Illumina HumanHap550 beadchips in healthy controls selected from Taiwan Han Chinese Cell and Genome Bank. The genotyping of the cases enrolled from Chang Gung Memorial Hospital was done with Illumina HumanHap610 beadchips. Results: We identified a significant association of chronic hepatitis B with 38 SNPs on chromosome 6. Twenty of them were replicated in an independent cohort of 282 controls and 410 cases. Six of the SNPs were incorporated in the second replication in 419 controls and 709 cases. We compared our final significant results to a nasopharyngeal cancer genome wide gene chip library, rs9277535 on HLA-DPB1 and rs7453920 on HLA-DQB2 indicated significant associations. Additional SNPs in BTNL2, HLA-DQA2 and HLADPB2 also showed marginal significant association. Conclusions: Our findings confirmed that genetic variants in the HLA-DPB1 and HLA-DQB2 locus are strongly associated with the risk of persistent infection with HBV. Other SNPs near or in HLA-DP or -DQ regions may also be involved in HBV persistence.
PS10-05
Levels of HBV DNA and not HBsAg are associated with biochemical flares after HBeAg seroconversion James Fung, Ching-lung Lai, Wai-kay Seto, Danny Ka-ho Wong, Man-fung Yuen
The University of Hong Kong
Background: The role of HBsAg levels in predicting subsequent flares in chronic hepatitis B patients after HBeAg seroconversion is not known Methods: Serum HBsAg and HBV DNA levels were determined in 224 CHB patients at 6-12 months after spontaneous HBeAg seroconversion. Serum HBV DNA levels were performed using Cobas Taqman assay. HBsAg titers were determined using Roche Elecsys HBsAg II assay (lower limit of detection 0.05 IU/mL). Patients were follow-up at 3-6 monthly intervals with routine liver biochemistry and viral serology performed. Flares was defined as ALT [29 upper limit of normal (ULN); the ULN for males and females was set at 30 and 19 U/L respectively. Results: The median age of HBeAg seroconversion was 37.5 years with a median follow-up of 83 months. Eighty-nine (39.7%) had evidence of biochemical flare occurring at a median time of 27 months after HBeAg seroconversion. Patients with flares had older age compared to those without flares (39 vs 35 years respectively, p = 0.005). There was no significant difference in HBsAg levels of patients with flares compared to those without (3.6 logs vs 3.51 logs IU/mL respectively, p = 0.946). In patients with flares, the HBV DNA was higher compared to those without flares (5.34 logs vs 4.60 logs copies/mL respectively, p = 0.007). Patients with HBV DNA[5 log copies/mL after HBeAg seroconversion had higher rates of subsequent flares compared to those with lower HBV DNA levels (p = 0.007 log rank). Conclusions: HBV DNA and not HBsAg levels after HBeAg seroconversion were associated with subsequent flares.
PS10-06
The association of HLA-DP locus with chronic hepatitis B and viral clearance in Japanese and Korean Nao Nishida Background: In the previous report, a genome-wide association study identified a significant association of chronic hepatitis B (CHB) with a region including HLA-DPA1 and HLA-DPB1 using 179 Japanese individuals with chronic hepatitis B and 934 control individuals (Kamatani et al. 2009 ). Methods: We conducted a genome-wide association study using an independent set of 181 Japanese individuals with CHB, 184 healthy controls and 185 individuals who were resolved from HBV (HBsAgnegative and anti-HBc-positive). In the following replication analysis, we carried out DigiTag2 assay and TaqMan assay using 596 individuals with CHB (252 Japanese and 344 Korean), 381 healthy controls (236 Japanese and 145 Korean) and 106 Korean HBVresolved individuals. Results: We identified significant associations of CHB with 5 SNPs in a region including HLA-DPA1 and HLA-DPB1 using a total of 777 CHB individuals and 565 healthy controls (rs3077; combined P = 2.16 9 10^(-19), OR = 0.458 and rs1431403; combined P = 3.26 9 10^(-16), OR = 0.495). We also identified strong associations of viral clearance with SNPs in the same region in the comparison between 525 CHB individuals and 291 HBV-resolved individuals (rs3077; combined P = 1.18 9 10^(-12), OR = 0.428 and rs1431403; combined P = 3.85 9 10^(-11), OR = 0.456). Conclusions: Our findings confirmed the significant association of CHB with the HLA-DP locus using an independent set of Japanese and Korean individuals. In addition, the HLA-DP locus would be associated with clearance of hepatitis B virus with several other genetic factors. Further investigations are necessary to clear the molecular mechanism by which the HLA-DP locus and/or other genetic factors confer the risk of CHB and lead viral clearance.
TCS26-01
The current and future aspect of HBsAg quantification on pegylated interferon therapy in chronic hepatitis B Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand
TCS26-02
Baseline and on-treatment predictors in nucleos(t)ide analogues therapy Chuan-Mo Lee Division of Hepatogastroenterology, Department of internal medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Chang Gung University College of Medicine, Taoyuan, Taiwan.
Chronic hepatitis B virus infection can manifest in a diversity of forms from asymptomatic carriers with normal histology to severe chronic liver disease including cirrhosis and hepatocellular carcinoma (HCC). At present, seven medications are approved including two forms of interferon (conventional and pegylated), and five oral nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine and tenofovir disoproxil fumarate). Long-term treatment has been shown to significantly reduce rates of disease progression to hepatic decompensation and cirrhosis or HCC. However, drug resistance is a serious risk of extended nucleos(t)ide analogue treatment. In real world settings, treatment response is determined by serum HBV DNA suppression, alanine aminotransferase normalization, hepatitis B e antigen seroconversion to hepatitis B e antibody, hepatitis B surface antigen loss, and liver histology improvement. Baseline and early ontreatment predictors during nucleos(t)ide therapy potentially provide for early differentiation between responders and non-responders, and allow for the possibility of personalized, response-guided therapy in CHB. Lower baseline HBV DNA has been reportedly associated with better sustained response. In addition, higher baseline ALT, younger age, higher grade of hepatic inflammation and genotype A or B were reportedly associated with better sustained response or HBsAg loss, albeit controversially. The choice of end point, antiviral agents, time of assessed response relative to baseline and disease status can determine which predictors carry weight. On-treatment predictors such as reductions of serum HBV DNA, and HBsAg and HBeAg levels can be used to predict treatment response and drug resistance. There is a paucity of data on the association of host genetic factors with treatment responses to antiviral agents.
TCS26-03
Do we need clinical predictors in high genetic barriers nucleos(t)ide analogues therapy? Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory
The introduction of nucleos(t)ide analogue (NA) therapy for chronic hepatitis B has resulted in the emergence of antiviral drug resistance which has become a major factor limiting treatment effectiveness.
Since antiviral drug resistance depends mainly on the genetic barrier of the drug, its detection becomes an important component of clinical management. Genetic barrier can be considered as the number of specific mutations required for drug resistance to develop and five HBV antiviral drug resistance pathways have been characterised. The first (rtM204V/I) is responsible for resistance to the L-nucleosides lamivudine (LMV) and telbivudine (LdT), and also entecavir (ETV) as rescue therapy in LMV-experienced patients. The second (rtN236T) accounts for adefovir (ADV) resistance, whilst the third pathway (rtA181T/V) is associated with resistance to LMV/LdT and ADV The fourth pathway is the emergence of the double substitution of rtA181T/V+rtN236T which results in resistance to tenofovir (TFV), ADV, LdT and LMV. In naïve patients treated with ETV, a fifth pathway has been described where 3 substitutions need to be selected out simultaneously: rtL180M+rtM204V plus codon changes at either one of rtI169 or rtT184 or rtS202 or rtM250. Finally, broad clusters of compensatory mutations which emerge during failing NA therapy will compromise future rescue therapy options with the newer more potent drugs such as ETV and TFV. Since resistance testing requires HBV pol sequencing, clinical predictors of genetic barrier, such as rate of decline of viral load over the first 24-48 weeks, may be useful surrogates for patient management.
TCS27-01
The role of radiotherapy in the management of biliary tract cancer Jong Hoon Kim
Asan Medical Center, Ulsan University College of Medicine
The role of radiotherapy in biliary tract cancer is unclear as we don't have enough data based on prospective randomized studies due to relatively small number of patients. But we have a few retrospective analyses which can tell us the possible benefit of adjuvant radiotherapy when used with or without concurrent chemotherapy. Current NCCN guidelines mention the role of chemoradiotherapy as one of the options for unresectable and incompletely resected cholangiocarcinoma. We will review the recent studies on surgical data and adjuvant treatment which tried to find out the role of adjuvant radiotherapy. Then we will discuss the future direction of treatments to find out optimal treatment for our biliary tract cancer patients.
TCS27-02
Chemotherapy in advanced biliary tract cancer Li-Tzong Chen National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
Palliative chemotherapy has been shown to improve the quality of life and prolong overall survival of patients with advanced biliary cancer (ABC) in three BSC-controlled studies. Although gemcitabine is frequently used as the standard or backbone of chemotherapy in clinical studies for ABC, the superiority of gemcitabine monotherapy over other chemotherapeutic agent had never been demonstrated in large-scale randomization trial(s). Similar for advanced pancreatic cancer, add-on strategy has frequently applied attempting to improve the therapeutic efficacy of gemcitabine in ABC. However, only few of combinations have ever proceeded to randomization trial comparing to gemcitabine monotherapy. Recently, a multicenter, randomized phase III trial (the UK ABC-02 trial) evaluating gemcitabine plus cisplatin (GC) versus gemcitabine alone (G) in patients with advanced or metastatic biliary tract cancer demonstrated a clear survival advantage for the combination arm (11.7 months versus 8.1 months in G arm, hazard ratio 0.68, P = 0.002). Similar therapeutic results were also observed in a randomized phase II trial conducted in Japan. Based on the results, GC is considered to be the new standard of care in ABC. On the other hand, due to its relatively easy in administration and low acute toxicity profile, oxaliplatin is an alternative option for combination with gemcitabine, and the doublet (GEMOX) is currently the favorable chemotherapy regimen in combination with molecular targeted therapy for clinical trials in ABC.
In conclusion, due to limited randomized, controlled trials, the global standard chemotherapy for ABC has not been established yet. Although GC is considered as a new standard for ABC after the disclosure of ABC-02 trial, however, the results need to be further validated in additional randomization phase III trials. In addition, new combinations and new compounds (either cytotoxic or molecular targeted agents) should be further explored for the treatment of this difficult tumor.
TCS27-03
Surgery in cholangiocarcinoma Ta predicated on effective communication policies. This is particularly so when complex decisions regarding treatment risks and benefits are being considered. This suggests a strong case for clear communications to patients to determine their expectations about treatment and where necessary the use of treatment decision aids (TDAs) and advanced care planning (APC) protocols to minimize difficult disjunctures between hoped for and actual prognosis. This presentation considers some of these issues and explores the associations between them and the establishment of shared and realistic therapeutic goals in HCC.
TCS28-02
Supportive care needs in patients with cancer -Clinical assessment and Implementation Patsy Yates
School of Nursing and Midwifery Queensland University of Technology
Recent years have seen increasing recognition of the multiple, complex supportive care needs experienced by people diagnosed with cancer. Current evidence indicates that a range of disease, treatment and psychosocial factors influence a person's need for support. The multidimensional nature of supportive care needs thus requires a comprehensive assessment of contributing factors, individual meanings and impacts associated with a person's needs, so that both pharmacological and non-pharmacological strategies can be effectively integrated into the person's care. There is a growing body of evidence to guide clinical assessment and implementation of multicomponent, tailored intervention approaches to reduce supportive care needs and improve outcomes for individuals with cancer.
TCS28-03
Fatigue in Patients with Liver Disease and Liver Cancer Shiow-Ching Shun
Department of Nursing, National Taiwan University
Fatigue is the most commonly experienced symptom in patients with liver disease, and it has a profoundly impact on quality of life. However, fatigue is under-estimated, under-treated, and without further management in patients with liver disease and liver cancer. The aims of this presentation are to: (1) introduce the concept and pathophysiology of fatigue in liver disease, (2) present a series of studies related to the impact of fatigue and its characteristics (intensity, duration, and perceived interference with functioning) on liver cancer patients and patients with chronic hepatitis C infected receiving interferon therapy in Taiwan, and (3) summarize the evidence-based practice for fatigue management including general approach and pharmacological interventions in patients with liver disease and liver cancer. In conclusion, a reasonable approach to manage fatigued patient with liver disease and further research directions are presented.
TCS29-01
Alcoholic liver disease: pathogenesis and new therapeutic targets Bin Gao
Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA.
Alcoholic liver disease (ALD) is a major cause of chronic liver disease worldwide and can lead to fibrosis and cirrhosis. The latest surveillance report published by the National Institute on Alcohol Abuse and Alcoholism showed that liver cirrhosis was the 12th leading cause of death in the United States, with a total of 29,925 deaths in 2007, 48% of which were alcohol related. The spectrum of ALD includes simple steatosis, alcoholic hepatitis, fibrosis, cirrhosis, and superimposed hepatocellular carcinoma. Early work on the pathogenesis of the disease focused on ethanol metabolism-associated oxidative stress and glutathione depletion, abnormal methionine metabolism, malnutrition, and production of endotoxins that activate Kupffer cells. In this presentation, I will briefly discuss recent studies that have characterized specific intracellular signaling pathways, transcriptional factors, aspects of innate immunity, chemokines, epigenetic features, microRNAs, and stem cells that are associated with ALD. Despite this progress, no targeted therapies are available. The cornerstone of treatment for alcoholic hepatitis remains as it was 40 years ago: abstinence, nutritional support, and corticosteroids. There is an urgent need to develop new pathophysiology-oriented therapies. Recent translational studies of human samples and animal models have identified promising therapeutic targets, which will be also discussed.
TCS29-02
Clinical Therapy of alcoholic liver disease (ALD) is based on the stage of the disease and the specific goals of treatment. Complications of cirrhosis are treated as in patients with non-ALD, with additional attention given to other organ dysfunction associated specifically with alcohol. Abstinence: Abstinence is the most important therapeutic intervention for patients with ALD. Abstinence has been shown to improve the outcome and decrease progression to cirrhosis, and to improve survival at all stages in patients with ALD. This improvement can be relatively rapid, and significant improvement was observed in 3 months. Thus immediate and lifetime complete abstinence from alcohol use is essential to prevent the progression of ALD. There is a significant risk of recidivism in patients who attempt to cut back but not stop drinking altogether. Over the course of 1 year, relapse rates range from 67%-81%.
Several medications have been tried to help sustain abstinence. The first agent disulfiram was supplanted by newer agents, such as naltrexone, a pure opioid antagonist which controls the craving for alcohol, acamprosate (acetylhomotaurine), a drug with structural similarities to the inhibitory neurotransmitter gamma amino butyric acid (GABA) which is associated with a reduction in withdrawal symptoms. There have been no studies that assess the efficacy of medications intended to reduce the craving for alcohol in patients with alcoholic hepatitis, although baclofen, a c-aminobutyric acid (GABA) B-receptor agonist, has recently been reported to promote short-term abstinence in a group of actively drinking patients with alcoholic cirrhosis.
The treatment of alcoholism is probably best handled by addiction experts. Thus multi-disciplinary approach with addiction specialists to tailor a program of psychological and social support for abstinence for each patient with ALD may be valuable. Until now psychotherapy to maintain abstinence has no clear evidence of benefit in patients with ALD because well designed studies have not been performed in patients with alcoholic hepatitis. Nutrition Therapy: The presence of significant protein calorie malnutrition is a common finding in alcoholics, as are deficiencies in a number of vitamins and trace minerals, including vitamin A, vitamin D, thiamine, folate, pyridoxine, and zinc. Patients who achieved nutritional goals and positive nitrogen balance had improved survival compared to those who did not. Thus oral or parenteral supplements have been recommended for patients with ALD at risk of undernutrition. The general consensus is that nutritional support results in a more rapid improvement in liver disease, but does not improve survival. Multiple feedings, emphasizing breakfast and a nighttime snack, with a regular oral diet at higher-than-usual dietary intakes (1.2-1.5 g/kg for protein and 35-40 kcal/kg for energy) seem beneficial. B-vitamins (especially thiamine), folic acid, and other vitamins should be administered according to Dietary Reference Intakes. Daily oral multi-mineral supplementation (without iron) should also be provided. Most patients are deficient in zinc, probably due to decreased oral intake and increased urinary loss. Thus, zinc replacement at a dose of approximately 200 mg/day should also be considered.
The optimal duration of vitamin and mineral support is not established and there are no published guidelines from nutrition or liver disease societies regarding the appropriate dosing of vitamin or mineral supplements in patients with alcoholic hepatitis. Steroids: The most extensively studied intervention in alcoholic hepatitis is the use of steroids, based on clinical trials that date back almost 40 years. The best available evidence suggests a dose of prednisolone (40 mg/day for 4 weeks then tapered over 2-4 weeks, or stopped, depending on the clinical situation) should be used, since it significantly increase short-term survival in patients with severe alcoholic hepatitis (Maddrey Discriminant Function [MDF] C32). An important issue in all studies of medical therapy is the possibility that these therapies may not be effective at an advanced stage of disease. Alcoholic hepatitis is unresponsive to corticosteroid treatment in approximately 40% of patients. No other treatment, including pentoxifylline, has been identified as effective in this subgroup. Also, the efficacy of combined treatment with pentoxifylline and corticosteroids has not been studied and warrants a randomized, controlled trial. There may be a ceiling beyond which medical therapies aimed at decreasing the inflammatory cascade may cause more harm than benefit. One study examined this issue, and suggested that patients with a MDF C54 were at a higher mortality risk from use of steroids than from not being treated. This cutoff, however, needs to be confirmed.
Corticosteroids should not be given to patients with a MDF of less than 32 or a MELD score of less than 21 since whose short-term survival approaches a rate of 90% and the risks of complications such as systemic infections outweigh the benefits. Some data suggest that the decision to stop prednisolone because of lack of efficacy can be determined by calculating the Lille score after 7 days of treatment (www.lillemodel.com). A Lille score greater than 0.45, seen in approximately 40% of patients with severe alcoholic hepatitis, signifies failure of prednisolone and warrants its discontinuation. Survival in this group of patients is less than 25%. Switching these patients to pentoxifylline treatment did not appear to improve survival. Anticytokine Therapy: A wealth of evidence suggests that dysregulated cytokines, including TNFa and a host of downstream cytokines play a pivotal role in the pathophysiology of alcoholic hepatitis. Thus, several agents have been studied targeting TNFa in particular. Pentoxifylline, an oral phosphodiesterase inhibitor which also inhibits the production of TNFa, showed reduction of the in-hospital mortality which related to a substantially lower likelihood of developing hepatorenal syndrome.
Other specific inhibitors of TNF that have been studied include infliximab, a monoclonal chimeric anti-TNF antibody, and etanercept, a fusion protein containing the ligand-binding portion of the human TNF receptor fused to the Fc portion of human immunoglobulin G1. In light of the poor clinical outcomes observed in the infliximab trials and the etanercept study, the use of these parenteral TNF inhibitors should be confined to clinical trials, and recommendations regarding specific therapy will need to await the results of these trials. Liver Transplantation: In the past, alcoholic hepatitis has been considered an absolute contraindication to liver transplantation (LT). But nowadays ALD is the second most common indication for LT for chronic liver disease in the Western world. Despite this, it is estimated that as many as 95% of patients with end-stage liver disease related to alcohol are never formally evaluated for candidacy for LT. This is attributed to perceptions that ALD is self-induced, the possibility of recidivism or noncompliance, and the shortage of organs. A 6-month period of abstinence has been recommended as a minimal listing criterion. But this requirement for a fixed abstinence period has not been shown to accurately predict future drinking by alcoholic candidates for LT. Predicting which patients will maintain sobriety is difficult, even among addiction specialists. In general, only a small fraction of those who undergo LT for ALD revert to heavy alcohol use or abuse.
Also there is a need for well-conducted studies of liver transplantation in carefully selected patients with severe alcoholic hepatitis that is not responding to medical management. Other Treatments: Many other therapeutic interventions have been studied in alcoholic hepatitis, but have not been able to show convincing benefit, including trials of antioxidants (vitamin E, silymarin, combination antioxidants), antifibrotics (colchicine), antithyroid drugs (propylthiouracil [PTU]), promoters of hepatic regeneration (insulin and glucagons), anabolic steroids (oxandrolone and testosterone), as well as calcium channel blockers (amlodipine), polyunsaturated lecithin, and a number of complementary and alternative medicines. S-adenosyl L-methionine (SAMe), a precursor to glutathione, also, did not demonstrate any significant benefit on total mortality, liver related mortality, complications or liver transplantation. Probiotics have been shown in preliminary reports to have anticytokine properties. Although promising, these treatments cannot be considered as standard treatment for ALD until further evidence of efficacy has been obtained. 
TSA-07
Genotypic resistance in the treatment of chronic viral hepatitis: Navigating the mazes Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory
Two concepts are important to an understanding of the development of antiviral drug resistance. First, viral infection is characterised by high levels of virus production and turnover. Second, the viral population in an infected person is highly heterogeneous. Antiviral drug resistance depends on:
1) Viral mutation frequency 2) The magnitude and rate of virus replication 3) Intrinsic mutability of the antiviral target site (usually a viral enzyme) 4) Selective pressure (potency) of the drug 5) Amount of replication space 6) Fitness of the resistant mutant. Other important factors include the ''genetic barrier'' of the drug which can be considered in the context of the number of specific mutations required for drug resistance to develop. Likewise, the ''molecular anatomy'' of the viral genome can also affect the emergence of drug resistance. In the case of HIV and HCV which have linear sequential genomes, resistance emerges rapidly, whilst for HBV with a circular genome with overlapping reading frames, that rate of resistance is reduced because multiple functions are affected by a single point mutation. In the latter example, polymerase mutations can directly affect the viral envelope due to this overlap, and so viral assembly and release can be negatively affected.
By understanding the main processes involved in selection of drug resistant viruses, it is possible then to implement ways to prevent it: 1) Maximise antiviral activity 2) Maximise genetic barriers to resistance 3) Increase pharmacologic barriers. In this way, the emergence of resistant viruses should be minimised.
TSA-08
The Yin and Yang of Translational Research in Viral Hepatitis T. Jake Liang Chief, Liver Diseases Branch, NIDDK, NIH Viral hepatitis has been a game changer in hepatology. The discovery of viral hepatitis has transformed the field from descriptive physiology to modern molecular medicine, in which we can actually alter the natural history and course of the disease. Early studies conducted from 1940-1960 demonstrated the existence of viral hepatitis. Distinct forms of the disease had already been implicated based on epidemiology and transmission studies then. The next five decades marked the extraordinary expansion in our knowledge of the various forms of hepatitis viruses and the diseases they cause. To date, we have identified all the major forms of viral hepatitis -although some may quibble that there are yet unidentified forms of hepatitis virus. We have also developed effective vaccines and therapies against some of the hepatitis viruses. It has now become a distinct reality that we are able to make a substantial impact on the public health burden of viral hepatitis in the next few decades. Viral hepatitis is the most common cause of acute and chronic liver disease in the world. More than half of the world populations have been exposed to various forms of hepatitis virus infection. About 400-500 million people have chronic liver disease as a result of chronic viral hepatitis. Chronic viral hepatitis is also the leading cause of liver cancer in the world, which has the fastest growing incidence among all the cancers in the Western world including the USA. Thus hepatitis virus infection is an urgent and critical public health problem in the world.
In this lecture, I will present the scientific advances in viral hepatitis, focusing on hepatitis B and C. I will discuss the impact of basic and translational scientific discoveries on clinical medicine and highlight important milestones in our understanding of both viral infections. Finally I will address what beholds the future in our ongoing efforts to combat this important public health burden in the world.
TSA-09
Biological analysis of hepatitis C virus using human hepatocyte chimeric mouse Kazuaki Chayama Hiroshima University ). Using this model we attempted to perform various infection experiments with HCV and found that infectivity of the viruses was strongly affected by the replacement rate of mice hepatocytes with human hepatocytes in the mouse liver. Now we are able to perform reverse genetics of the virus using recombinant DNA techniques.
We cloned an infectious genotype 1b HCV clone KT-9 from a patient who developed acute infection after needle stick exposure from an infected patient. The cloned virus did not replicate in cell culture. However, when we injected transcribed RNA into mice liver, the mice developed viremia. Using this model, we tested the anti-viral effect of various agents and proved that some of them are quite effective.
Recently, amino acid (aa) substitutions of core 70 and 91 and in the NS5A interferon sensitivity determining region (ISDR) of HCV as well as genetic polymorphisms in the host IL28B locus have been shown to affect outcome of interferon-based therapies. We created mutant strains with core and ISDR substitutions and tested the replication ability and response to the therapy in mice with different IL28B alleles. While aa substitutions in the ISDR significantly impaired infectivity and replication ability of the virus, core aa70 and 91 substitutions did not. The effect of IFN treatment was similar in core wild-type and mutant viruses. Interestingly, virus titer was significantly higher in mice with the favorable IL28B allele (rs8099917TT and rs12979860CC) in the transplanted hepatocytes than in mice with hepatocytes from rs8099917TG and rs12979860TT donors. However, the effect of IFN was significantly greater, and intrahepatic expression levels of IFN-stimulated genes were significantly higher in mice with the favorable IL28B allele.
We further showed that combination therapy with newly developed direct antiviral agents eliminate the virus without interferon following only four weeks of therapy.
TSA-10
Perspectives in HBV and HCV therapy Patrick Marcellin Viral Hepatitis Research Center, Hôpital Beaujon; University of Paris Spectacular progress has recently been made in the therapy of chronic hepatitis B and chronic hepatitis C and new strategies are evaluated with the aim to provide easier and more efficient therapy.
In chronic hepatitis B, current therapy with the most potent analogues induce a complete virological response with improvement of the liver disease in the large majority of patients. The combination of a potent analogue (entecavir or tenofovir) with pegylated interferon might accelerate HBsAg decline and increase HBsAg loss rate, the ultimate goal of therapy. Quantitative HBsAg is a new tool with potential important applications both for the prognosis of the liver disease and the prediction of response to therapy. The significance of quantitative HBsAg with regard to cccDNA and the immune response needs to be understood. Combinations of available drugs or new drugs need to be developed to clear HBV infection.
In chronic hepatitis C, triple therapy with first generation protease inhibitors, telaprevir or boceprevir, in patients with HCV genotype 1, has shown improved efficacy with approximately sustained virological response rates of 70%. Many new direct antiviral agents (DAA) are under evaluation and the results of DAA combinations have been spectacular in genotype 1 as well as in other genotypes. We are convinced that in the near future, safe combinations of oral DAA, administered for a short duration, will eradicate HCV infection whatever the genotype, in almost all patients. Hopefully, these therapies will be available at a reasonable cost worldwide to cure all patients with this disease.
BP-01_25064
Hepatology Perisinusoidal fibrosis is associated with transient elastogra- Background: Perisinusoidal fibrosis (PF) may be related to many causes, including metabolic disorders. Steatosis may be associated with the progression of liver fibrosis but its evaluation by non invasive methods remains a challenge. Controlled Attenuation Parameter (CAP) evaluating liver steatosis based on FibroScan. Methods: 136 CHB patients were prospectively included (63% men, age = 38ÿ3y). All patients underwent within 60 days both liver biopsy (LB) and FibroScan Results: CAP was only associated to steatosis (p\10-6). PF was mild/ absent in 45%, moderate in 39% and marked in 16% of patients. In univariate analysis, PF was correlated with TE (p\10-4) and CAP (p\10-3), with fibrosis (p=0.002) and activity (p\10-5), at the limit of significance for steatosis and NASH (p=0.06) and not with metabolic syndrome and HBV-DNA levels. In multivariate analysis PF was associated with TE and CAP, activity and steatosis. Conclusions: CAP is an accurate tool to detect and quantify steatosis in CHB patients. Moderate to marked PF was observed in 55% of our CHB patients. PF is independently associated with TE and CAP measurements.
BP-02_9260
Telbivudine therapy for chronic hepatitis B: 3-year observational study in the clinical setting Fei Li
Tianjin Infectious Disease Hospital
Background: To observe telbivudine efficacy on HBV suppression and HBeAg seroconversion, determine optimal treatment strategies based on the baseline characteristics of patients and investigate long term treatment efficacy based on HBV DNA response at 12 weeks. Methods: Sixty HBeAg-positive CHB patients received 600 mg/d telbivudine orally for 156 weeks. HBV DNA was quantified by realtime fluorescent PCR with a lower detection limit of 500 copies/mL. Efficacy markers included HBeAg and ALT. Results: Patients were 73% male with a mean age of 32. Mean HBV DNA (log10) was 7.5 and mean and median ALT was 146 and 111 IU/L, respectively. During treatment 71% of patients had undetectable HBV DNA at week 12, 82% at week 52 and 90% at week 156. Fifty percent of patients had HBeAg loss at week 156 and 47% of patients (28/60) were considered HBeAg seroconverters. ALT normalization was achieved by 80% of patients at week 12, 92% at week 52, and 95% at week 156. Of the 71.7% of patients (43/60) with undetectable HBV DNA at week 12, 97.7% (42/43) had undetectable HBV DNA and 51.2% (22/43) showed HBeAg seroconversion at week 156. Six patients showed resistance to treatment at week 156, of which 1 patient had undetectable HBV DNA at week 12. One patient reported a peripheral neuropathy with CK elevation. Conclusions: In this study telbivudine treatment had a good safety profile and achieved both basic (HBV DNA undetectable) and satisfactory (HBeAg seroconversion) goals. HBV DNA responses at week 12 are useful in predicting long term treatment outcomes.
BP-03_10110
Imbalance of TH1/TH2 cytokines induced by HBeAg in patients with chronic hepatitis B Yaping Han, Jun Li
The First Affiliated Hospital with Nanjing Medical University Background: To study the immunoregulating effect of HBeAg on peripheral blood monocytes (PBMCs) from patients with chronic hepatitis B (CHB). Methods: After incubated with recombinant HBeAgAthe B7-H1/PD-1 expression on PBMCs from CHB patients and healthy controls was measured by Results: Th1-type cytokines (IFN-^) of supernatant was reducedAwhereas Th2-type cytokines (IL-6, IL-10) of supernatant and the expression of B7-H1 on PBMCs was increased after PBMCs stimulated with HBeAg (P\0.05); The production of IFN-^in CD3+CD4+T cells was significantly lower in HBeAg-positive CHB patients in comparison with HBeAg-negative CHB patients (P\0.01), on the contrary, IL-4 in HBeAg-positive CHB patients was increased (P\0.05). Meanwhile, B7-H1 expression on PBMCs from HBeAgpositive CHB patients was markedly higher (P\0.05). Conclusions: HBeAg was able to down-regulate the production of Th1-type cytokines (IFN-^)A and up-regulate the secretion of Th2-type cytokines (IL-6, IL-10) and the expression of B7-H1 on monocytes. These changes are conducive to the formation of immune tolerance to HBV. Therefore, HBeAg may play an important role in immune tolerance to chronic HBV infection.
BP-04_4022
Hepatic lymphoproliferative disorder mimicking hepatocellular carcinoma Wei-Chen Lin, Shu-Jung Tsai, Horng-Yuan Wang, Shou-Chuan Shin Mackay Memorial Hospital, Taipei, Taiwan Hepatol Int (2012) 6:44-66 57
Background: Hepatic lymphoproliferative disorder occur more often in patients with chronic viral hepatitis. It is also related to EBV infection and immune suppression after solid organ transplantation.
Methods: We presented a patient with typical image of hepatocellular carcinoma but pathology showed hepatic lymphoproliferative disorder.
Results: This 74-year-old female presented with intermittent periumbilical dull pain and weight loss for 1 year. Ultrasonography showed fatty liver and a well defined hypoechoic nodule about 1.8 cm in S7. Serology for hepatitis B and hepatitis C virus were negative. CEA and AFP were in normal range. Abdomen CT and MRI demonstrated a small nodule with similar enhancement pattern (hyperdensity at artery phase and wash out at portal venous phases) in the S7 of right liver. The patient underwent partial hepatectomy under the presumptive diagnosis of hepatoma. Microscopically, the lesion show proliferation of lymphocytes.
Immunostaining of the tumor cells showed reactivity for CD2, CD3, CD4, CD5, CD8, CD20, Pax 5 but not for CD10. Paraffine block showed presence of T cell receptor-gamma gene clonal rearrangement. EBV study was negative. Based on these findings, the liver tumor was diagnosed as primary hepatic lymphoproliferative disorder. The patient remained in stable health without additional therapy for greater than 2 years. Conclusions: Lymphoproliferative disorder is at increased risk for the development of non-Hodgkins lymphoma. This patient had premalignant lymphoid hyperplasia change. The best method of hepatoma diagnosis is still hepatic biopsy if a tumor measuring 1V2 cm in a non-cirrhotic liver shows typical features of HCC in two dynamic image.
BP-05_13300
Comparison of responses of pegylated interferon alpha-2a VS. alpha-2b in the treatment of chronic hepatitis C Po-Hao Liao
Mackay Memorial hospital, Taipei
Background: Ribavirin combined with either pegylated interferon alpha-2a or apha-2b is the standard of care for chronic hepatitis C. This study compared the virologic response of PegIFNalpha-2a and alpha-2b. Methods: We retrospectively reviewed 348 patients with chronic hepatitis C from 2009-11 to 2011-6 Background: The roles of interferon regulatory element (IRE) in hepatitis B virus (HBV) genome on inhibitory effect of interferon against HBV replication are controversial in vitro studies. The present study was undertaken to determine the functional characterization of HBV-IRE sequence in vivo in hydrodynamically-injected mice. Methods: Wild type or IRE mutant HBV replication-competent mice were firstly established. Twenty-four hours later, mice were treated with polyinosinic-polytidylin acid (polyI.C) or phosphate-buffered saline (PBS) via intraperitoneal injection 3 times at 24 hour intervals. The HBV RNA and HBV DNA replication intermediates in the liver were analyzed. Results: PolyI.C inhibited viral replication, and increased the level of 2',5'-oligoadenylate synthase mRNA transcripts, which is a known marker of INF-\/] induction. Between wild-type and IRE-mutant HBV replication-competent mice, the levels of HBV RNA and HBV DNA replication intermediates were similar. After PolyI.C treatment, the decreasing of HBV RNA was similar between two groups, but HBV DNA replication intermediates decreased significantly less in IREmutant than wild type HBV replication-competent mice. Conclusions: IRE mutant didnt influence the transcription and replication of HBV, but reduced the inhibitory effect of interferon on HBV replication. These finding suggested that HBV-IRE played a role in the antiviral effect of interferon against HBV.
BP-12_6012
Deficiency of IL-15 enhanced the susceptibility to acetaminophen-induced liver injury in mice Heng-Cheng Chu, Hsien-San Hou, Tsai-Yuan Hsieh, Ching-Len Liao, Tien-Yu Huang
Yes
Hepatol Int (2012) 6:44-66 59
Background: Although direct necrotic effect on hepatocyte plays a major role in acetaminophen (APAP)-induced liver injury (AILI), prolonged secondary inflammatory response through innate immune cells and cytokines also significantly contributes to APAP hepatotoxicity. Interleukin (IL)-15, a pro-inflammatory cytokine, not only regulates adaptive immune system but also influences development and function of innate immune cells. Therefore, we tried to evaluate whether IL-15 plays a role in AILI. Methods: Wild-type (WT), IL-15 knockout (Il15-/-) and IL-15 receptor alpha chain knockout (Il15ra-/-) mice were treated with APAP to elicit acute hepatitis. Animal survival, liver damage, APAP metabolism in liver and inflammatory response were evaluated in these mice.
Results: Unexpectedly, discordant susceptibilities to AILI were found in Il15-/-and Il15ra-/-mice. A stronger activation of pro-inflammatory cytokines/chemokines was noted in Il15-/-mice, as compared with the other two strains of mice. Sub-analysis of hepatic infiltrated monocytes in Il15-/-mice revealed a greater neutrophil influx, along with higher hepatic induction of inducible nitric oxide synthase (iNOS), than WT mice. In addition, hepatic hemeoxygenase-1 (HO-1) was partially suppressed in Il15-/-mice, but not in WT or Il15ra-/-mice after APAP challenge. Interestingly, depletion of Kupffer cells (KCs) and neutrophils did not alter the vulnerability to APAP in Il15-/-mice. However, injection of galactosamine, a hepatic transcription inhibitor, reduced the heightened APAP sensitivity in Il15-/-mice, but showed no effect on WT and Il15ra-/-counterparts.
Conclusions:
We demonstrated that deficiency of IL-15 in mice enhanced the susceptibility to AILI, whereas the increased APAP sensitivity is IL-15 receptor alpha chain independent. 
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microRNA-224 involves in cell proliferation, migration, invasion and antiapoptosis of HCC Yizhou Zhang, Shoichi Takahashi
Hiroshima University
Background: HCC (Hepatocellular carcinoma) is the fifth most common cancer worldwide, however, limited is known about the mechanisms leading to pathogenesis. Since alterations of microRNA expression have been detected in a broad range of biological processes including cancer, we explored miRNA dysregulation in HCC and demonstrated its characteristics. Methods: We investigated the expression changes of several cancerrelated miRNAs in HCC tissues, and isolated miR-224 as a study target. We further characterized the expression profiles of miR-224s targets using cDNA microarray, and validated the altered expression with real-time PCR and western blot. Among the miRNAs we detected, miR-224 was the most significantly up-regulated in HCC tissues comparing to normal or HCC adjacent non-tumorous liver tissues.
Results: From the microarray analysis and miRNA target prediction analysis, 68 putative gene targets were observed to be altered significantly when miR-224 overexpressed. Among those genes, CDC42, CDH1, Pak2, BCL-2 and MAPK1 were confirmed as prime targets of miR-224, whose expression levels were significantly altered at both mRNA and protein levels. Moreover, the alteration of the gene targets expression was shown in HCC tissues in almost same manner. Conclusions: By directly binding of miR-224 to its gene targets, the expression of miR-224 could influence the process of cell proliferation, migration, invasion and anti-apoptosis. MiR-224 might play a leading role in the phenotype of HCC cells. The results strongly implicated miR-224 maybe an essential factor for HCC development and progression. The First Affiliated Hospital with Nanjing Medical University
BP-15_14047
Background: To investigate the changes of the frequency and function of HCV-specific-CTLs of chronic HCV patients before and after Peg-IFN-2a treatment, explore the relationship between these changes and antiviral efficacy. Methods: By using flow-cytometry-technique with HLA-A0201 restrict epitope HCV core and NS3, we dynamically quantitatively detected the frequency of HCV-specific-CTLs in the peripheral blood of the HCV patients and the expression of granzyme-B/perforin in the CTLs, meanwhile, measured the HCV RNA and ALT, and analyzed the relations between the changes of frequency and function of HCVspecific-CTLs and ALT level, HCV clearance.
Results:
Conclusions: Peg-IFN-2a treatment could increase the frequency of HCV specific CTLs in the peripheral blood of HCV patients and the expression of HCV specific granzyme and perforin; The high expreesion of HCV specific granzyme and perforin might play a important role in the clearance of HCV. 
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Acute Acalculous cholecystitis in children: relationship between wall thickness in ultrasound and low serum albumin Fu-Chen Huang, Chih-Jen Chen
Kaohsiung Chang Gung Memorial Hospital
Background: Acute acalculous cholecystitis (AAC) is an inflammation of the gallbladder in the absence of demonstrated calculi. It comprises 5% to 10% of all cases of acute cholecystitis in adults and appears to be even less frequently diagnosed in children.
Methods:
The records of all patients with sonographyly proven acute acalculous cholecystitis seen at the Kaohsiung Chang Gung Memorial Hospital from November 2007 to November 2010 were obtained. Results: Fifty-nine children with acute acalculous cholecystitis (AAC) were treated over a 13-year period (32 male and 27 female). Their ages ranged from 2 months to 18 years (68 Conclusions: Acute acalculous cholecystitis is rare in children and its wall thickness has good correlation with age of onset in ultrasound. It is associated with low albumin levels and less nausea and vomiting if the ratio between gallbladder wall thickness and age of onset is more than one. Background: Despite the initial belief that non-alcoholic fatty liver disease (NAFLD) is a benign disorder, it is now recognized that fibrosis progression and hepatocellular carcinoma occurs in a significant number of patients. Here, using in vitro model, we investigate the effects of hepatic lipid accumulation on liver fibrogenesis and carcinogenesis. Methods: Primary rat hepatocytes (PRH) and human hepatoma cell line (HepG2) were stimulated with saturated fatty acid palmitate. Intracellular lipid accumulation-mediated reactive oxygen species (ROS) production, NADPH oxidase (gp91 subunit), NFeB p65 nuclear translocation, inflammatory genes expressions, \-SMA protein expression and sphere formation, were assessed. Results: Primary rat hepatocytes (PRH) and human hepatoma cell line (HepG2) incubated with the saturated fatty acid palmitate were demonstrated to induce intracellular lipid accumulation-mediated reactive oxygen species (ROS) production, NADPH oxidase (gp 91 subunit), NFeB p65 nuclear translocation and up-regulation of inflammatory genes. Subsequently, activation of rat hepatic stellate cells (HSC-T6) was observed when treated with palmitate directly or incubated with conditioned media (CM) from PRH treated with palmitate. Notably, palmitate could significantly enhance sphere formation in HepG2 cells, whereas, NAC,PDTC, two known NFeB inhibitors and DPI, a chemical inhibitor of the NADPH oxidase could reduce palmitate-induced sphere formation in HepG2, suggesting that lipid accumulation could enrich the potential cancer stem cell (CSC) subpopulations in cancerous cells, probably through NFeB signaling pathway and oxidative stress. Conclusions: In summary, our in vitro data demonstrate a potential mechanism for the pathophysiological role of hepatic lipid accumulation in liver fibrogenesis and carcinogenesis.
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Switching to telbivudine compared with adding on adefovir in HBeAgpositive chronic hepatitis B with unsatisfactory response to interferon Xuesong Liang peripheral myeloid dendritic cells (mDC) and plasmacytoid dendritic cells (pDC) and the cell surface molecule expression of monocyte derived dendritic cells was assessed, IL-12, IL-10 and INF\ levels were also detected. Results: LdT resulted in HBV DNA levels below limits of detection in 6/10 patients at 3 months and 10/10 patients at 6 months. ALT normalization was achieved by 4/10 and 7/10 patients at 3 and 6 months, respectively. After 6 months 3/10 patients were HBeAg(-), 1/10 was HBeAb(+) and no patient was HBsAg(-). Frequency and absolute numbers of pDC significantly increased at 3 months (p\0.01) and were comparable to normal controls at 6 months. Interferon-\ production by pDCs was not significantly affected by LdT. Although mDC cell counts were unchanged, mDC-induced lymphocyte proliferation was increased from 3 months. LdT significantly affected HLA-DR and PD-L1 surface expression (p\0.05) but not CD40 or CD80 expression. Production of IL-10 by mDC was decreased while the production of IL-12 was sharply increased. Conclusions: LdT increased pDC numbers and the ability of mDCs to induce proliferation of T cells and production of IL-12. The improved function of peripheral mDC in CHB patients may be associated with upregulated HLA-DR and down-regulated PD-L1 expression.
BP-25_9264
Efficacy of telbivudine for chronic hepatitis B combined with HBV associated glomerulonephritis Zhenwu Yan
Peoples Hospital of Weifang
Background: The aim of the present study was to evaluate the efficacy of telbivudine (LDT) in patients with chronic hepatitis B virus (HBV) infection and HBV-associated glomerulonephritis (HBV-GN). Methods: Seven patients with chronic HBV and HBV-GN were treated with LDT (600 mg/d) for 52 weeks. Efficacy outcomes included complete remission (urine protein \0.3 g/d, stabilized kidney function and normalized alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels), partial remission (urine protein/24 hours decreased [50% from baseline, stabilized kidney function, ALT and AST levels decreased [50% from baseline), and inefficiency (no improvement in symptoms or laboratory tests from baseline). Results: At baseline, all 7 patients were HBeAg-positive with HBV DNA levels [5 log10 copies/ml, ALT Conclusions: In patients with HBV and HBV-GN, LDT treatment demonstrated satisfactory efficacy including reduction of urine protein over 24 hours and normalization of liver function tests as well as a favorable safety profile.
BP-26_9263
Efficacy and safety of telbivudine in preventing hepatitis B virus perinatal infection Zhancheng Yao
Second Hospital of Shantou University Medical College
Background: To evaluate the efficacy and safety of telbivudine (LDT) in preventing HBV perinatal infection. Methods: HBsAg-positive pregnant women with CHB were treated with LDT (600 mg/d), or underwent no treatment, starting at 28 weeks of pregnancy through 4 weeks post-partum. Infants from both groups were treated with hepatitis B immune globulin and HBV vaccines. HBV serum markers, HBV DNA levels and liver and kidney function tests were measured in mothers and infants, who were followed for up to 28 months. Perinatal infection was diagnosed if serum HBsAg positivity was detected at birth and persisted for more than 6 months. Results: Baseline characteristics were similar between the LDT (n=28, 29 infants) and control (n=30, 30 infants) groups. Compared to baseline, HBV DNA and ALT levels before delivery decreased in the LDT group but did not change in the control group. The perinatal infection rate of infants in the LDT group was significantly lower than that of the control group (0% vs. 13.3%, respectively, P\0.05). Elevated ALT levels before delivery were observed in 4 occurring perinatal infection mothers of the control group. Elevated CK levels (not requiring intervention) were observed in 3 LDT patients and 2 control patients. No complications due to delivery were noted in either group. In the LDT group, 29 infants were HBsAb-positive. Conclusions: Administration of LDT at later pregnancy in women with CHB could markedly reduce their HBV DNA levels before childbirth and effectively decrease perinatal HBV infection, and was safe for both mothers and their infants.
BP-27_9270
Entecavir Background: Chronic hepatitis B is one of the most common epidemic diseases in China. The aim of the trial was to evaluate the efficacy of Entecavir maleate on hepatitis B virus (HBV). Methods: In this randomized double-blind multicenter clinical trial conducted in china, 220 patients with e antigen (HBeAg)Vpositive chronic hepatitis B who had not previously received a nucleoside analogue were randomly assigned to receive either 0.5 mg of entecavir maleate(CTTQ) or 0.5 mg of Entecavir (Baraclude, BristolMyers Squibb) daily for 48 weeks. Results: There is no significant difference between the entecavir maleate group and Baraclude group in the rate of undetectable serum HBV DNA at 48 week(52% vs. 60%, P=0.3373For 31% vs. 35%, P=0.5642 according to the LLOQ]Lower Limit of Quantification^\300copies/ml or LLOQ\50copies/ml). Normalization of alanine aminotransferase was similar in two groups (83% vs. 75%, P =0.2356). The mean reduction in serum HBV DNA from baseline to week 48 was similar between the group of entecavir maleate and Baraclude (5.5 vs. 5.6 log copies per milliliter, P=0.7967). HBeAg seroconversion occurred in 10 % of entecavir maleate treated patients and 8% of those treated with Baraclude (P =0.6317). Safety and adverse-event profiles were similar in the two groups. Conclusions: Among patients with HBeAg-positive chronic hepatitis B, there were no significant difference on the rates of virologic response and biochemical normalization between the group of entecavir maleate and Baraclude. The safety was similar between the two groups.
BP-28_9265
The efficacy of switching to telbivudine therapy in HBeAg-positive chronic hepatitis B patients with partial response to pegylated interferon Zhanlian Huang, Liang Peng, Yubao Zheng, Ying Yan, Zhixin Zhao, Yanling Fu, Zhiliang Gao
The Third Affiliated Hospital of Sun Yat-Sen University Background: To study the efficacy and safety of switching to telbivudine (LdT) therapy in patients with HBeAg-positive CHB and partial response to 52 weeks of pegylated interferon (PEG-IFN) treatment. Methods: Eighteen HBeAg-positive CHB patients with partial response to PEG-IFN were switched to LdT(600mg/d) for 48 weeks. HBeAg, HBeAb, HBV DNA quantification, ALT and CK levels were measured at 0, 12, 24, 36 and 48 weeks. Partial response was defined as a Results: Baseline HBeAg levels (136 ± 344 COI) and HBV DNA levels (4.35 ± 2.13 log10 IU/mL) were relatively low due to partial response to PEG-IFN. After 48 weeks of LdT, the HBeAg seroconversion rate was 61% with an average 80.9% decline in HBeAg levels by 12 weeks. By 24 weeks, all patients achieved undetectable HBV DNA (\100 IU/mL) and ALT normalization. For the 7 patients who did not achieve HBeAg seroconversion, HBeAg levels decreased an average of 86.3% within 12 weeks and remained below 20 COI during treatment with HBV DNA levels declining to undetectable levels by 24 weeks. LdT therapy was well tolerated and no serious adverse effects were observed. Conclusions: In HBeAg-positive CHB patients with partial response to PEG-IFN at week 52 switching to LdT therapy was effective and safe. After 48-weeks of LdT therapy, the HBeAg seroconversion rate was 61%, all patients achieved undetectable HBV DNA.
BP-29_9256
Efficacy and safety of using telbivudine combination with adefovir dipivoxil in high viral load HBeAg-positive chronic hepatitis B patients Zutao Chen, Yan Li, Jiancheng Wu, Jianhe Gan, Weifeng Zhao, Erping Luo, Ailan Qin, Minhua Jiang, Xiaoping Huang, Tingting Feng and p=0.003), and trended towards positive correlation with Ishak fibrosis stage (p=0.062). Although circulating HBV DNA correlated with intrahepatic HBV DNA and cccDNA (p=0.002 and 0.00015), it did not correlate with HAI or ALT. Conclusions: Intrahepatic HBV DNA levels were significantly associated with severity of liver necroinflammation, while circulating HBV DNA was undetectable in most cases, and not associated to liver necroinflammation. Assessment of intrahepatic HBV DNA may be required for more accurate indication of histologic damage in the liver than can be ascertained by serum HBV DNA levels.
